Time New York: Sun 19 Nov 00:04 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Agenus (AGEN) Reports In Line Q3 Loss, Sales Miss Estimates

Zacks

Agenus Inc. AGEN is a Lexington, MA-based development-stage company focused on the discovery and development of checkpoint modulators, vaccines and adjuvants for the treatment of cancer.

The company earns revenues primarily through fees received under collaboration and license agreements, which not only provide it with funds in the form of upfront and milestone payments and future royalties, but also validate the company’s proprietary product platform. In Mar 2017, the company undertook certain restructuring activities in order to cut costs and focus on developing key product candidates.

With no approved product in its portfolio yet, investor focus should remain on pipeline updates by the company. The company has three platform technologies for the development of its candidates – Retrocyte Display, SECANT and phage display – each designed to produce quality human antibodies. The company has several early-to-mid stage candidates in its portfolio.

Agenus’ track record has been mixed so far. The company has surpassed estimates thrice in the trailing four quarters and missed the same on one occasion, bringing the average positive surprise to 4.27%.


Currently, Agenus has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings:Agenus reported in line loss in the third quarter of 2017. Our consensus called for a loss of 37 cents per share, which was in line with loss reported by the company.

Revenue:Revenues, however, missed expectations. Agenus posted revenues of $3.4 million, compared to our consensus estimate of $4 million.

Cash and Cash Equivalents:Cash, cash equivalents and short-term investments were $70.1 million as of Sep 30, 2017 compared with $76.4 millionas of Dec 31, 2016.

Share Price Impact: In-active in pre-market trading.

Check back later for our full write up on AGEN earnings report later!

Zacks' Hidden Trades

While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?

Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum…from stocks under $10 to ETF to option movers…from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.

Click here for Zacks' secret trade>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.